Clinical trials · New York, NY
Meningioma clinical trials in New York
We’re tracking 9 recruiting meningioma studies with a site in or near New York — including Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT07428616RecruitingPhase 2
Study of Zanzalintinib for recurring meningioma
This trial tests a drug called Zanzalintinib for people with meningioma that has come back or grown despite past treatments. It aims to see if the drug can stop or slow tumor growth.
New York, New YorkAges 18 years+ - NCT07533942RecruitingPhase 2
Testing JZP3507 for Recurrent Grade 2 or 3 Brain Tumors
This study tests a new drug called JZP3507 for people with meningioma (a type of brain tumor, grades 2 or 3) that has come back or grown despite previous treatment. The goal is to see if this medication can slow or shrink the tumor.
New York, New YorkAges 18 years+ - NCT06377371RecruitingPhase 4
Intraoperative tracing of meningioma with copper-64 DOTATATE
This trial tests a special imaging agent called [Cu64]DOTATATE that helps surgeons see meningioma tumors during surgery. It may make tumor removal more complete and safer.
New York, New YorkAges 18–99 - NCT03180268RecruitingPhase 3
Watch or radiate after surgery for grade II meningioma
This trial studies whether people with a grade II meningioma that has been completely removed by surgery should be monitored only or treated with radiation. It may help reduce the risk of the tumor coming back while balancing radiation side effects.
New York, New YorkAges 18 years+ - NCT02523014RecruitingPhase 2
Drug combo for meningioma that keeps growing despite treatment
This Phase 2 trial tests several targeted medicines (given together or by specific assignment) for meningiomas inside the brain that are progressing or not fully removed after surgery. It may help slow the tumor’s growth and improve symptoms by blocking tumor growth pathways.
New York, New YorkAges 18 years+ - NCT04427384Recruiting
Brain tumor patients treated with GammaTiles registry
This study is a patient registry for people with brain tumors who had surgery to remove as much as safely possible and then had GammaTiles placed. It mainly collects information and follow-up imaging to understand how patients do after the treatment.
New York, New YorkAges Any age - NCT04081701RecruitingPhase 4
Ga-68 DOTATATE PET/MRI for somatostatin-receptor brain tumors
This trial tests how well a special scan (Ga-68 DOTATATE PET combined with MRI) helps diagnose and guide treatment for certain brain tumors that have somatostatin receptors. It may help doctors better find tumor recurrence or remaining tumor after treatment.
New York, New YorkAges 18–100 - NCT04374305RecruitingPhase 2
Study tests targeted treatments for NF2 tumors
This trial studies targeted medicines in people with neurofibromatosis type 2 (NF2) who have growing tumors on scans. The goal is to slow tumor growth and improve symptoms by testing different drug combinations in separate study groups.
New York, New YorkAges 12 years+ - NCT05425004RecruitingPhase 2
Cabozantinib for recurrent or worsening meningioma tumors
This Phase 2 trial studies cabozantinib, a targeted pill medicine, for meningioma that has come back or is getting worse after standard treatment like surgery or radiation. It aims to shrink tumors and slow progression when other options may have limited benefit.
New York, New YorkAges 18 years+
Hear when a new Meningioma trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Meningioma trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting meningioma studies listed above.
- Memorial Sloan Kettering Cancer Center · 4 studies
- Columbia University Irving Medical Center · 3 studies
- NYU Langone Health · 3 studies
- Weill Cornell Medicine · 3 studies
- Jersey Shore University Medical Center · 2 studies
- Memorial Sloan Kettering Basking Ridge · 2 studies
- Memorial Sloan Kettering Bergen · 2 studies
- Memorial Sloan Kettering Commack · 2 studies
What taking part in a meningioma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting meningioma studies in New York.
Common questions
- Are there meningioma clinical trials near New York?
- Yes. We're currently tracking 9 recruiting meningioma studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a meningioma study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a meningioma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New meningioma studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.